AX-2025-020361
Liraglutide · 10 mg declared · Xi'an Mokemei Biotechnology Co., Ltd. · lot MKM-2508-P3929
- Report ID
- AX-2025-020361
- Compound
- Liraglutide
- Compound class
- Incretin analogues and co-agonists
- Supplier
- MKM — Xi'an Mokemei Biotechnology Co., Ltd.
- Batch / lot
- MKM-2508-P3929
- Declared label claim
- 10mg
- Laboratory
- Janoshik Analytical
- Assay date
- 09 Sep 2025
- Submitted
- 13 Sep 2025
- Quarter
- 2025-Q3
- Submitter
- Contributor #A-4471
- Sample provenance
- Supplier-supplied
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 98.55 | % area | ≥ 97.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.45 | % area | ≤ 2.5 | PASS |
| Largest single impurity | RP-HPLC — deamidated (Asn→Asp, +1 Da) | 1.04 | % area | ≤ 1.00 | FAIL |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 3748.9631 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 3748.9500 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -3.5 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 84.65 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 83.42 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 12.40 | mg | 10 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 10.344 | mg | 10 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 103.4 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 6.99 | % | ≤ 8.0 | PASS |
| Counter-ion (TFA) | anion-exchange ion chromatography | 7.88 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.48 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | Off-white lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 3.51 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 17.14 | min | 17.28 ± 0.40 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.10 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 30,171 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs γ-Glu regioisomer | 1.01 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Liraglutide — main peak | 17.14 | 4,789,836 | 98.55 | — |
| 2 | deamidated (Asn→Asp, +1 Da) | 16.66 | 50,547 | 1.04 | +0.984 |
| 3 | palmitoyl bis-adduct (+238 Da) | 20.02 | 13,609 | 0.28 | +238.230 |
| 4 | des-palmitoyl liraglutide (−238 Da) | 13.70 | 3,402 | 0.07 | -238.230 |
| 5 | γ-Glu regioisomer | 17.55 | 1,944 | 0.04 | 0.000 |
| 6 | des-His1 truncate (−137 Da) | 16.12 | 486 | 0.01 | -137.059 |
| 7 | liraglutide dimer | 20.29 | 486 | 0.01 | +3748.963 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 3748.9631 Da, computed from C172H265N43O51. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 6+ | 625.8345 | 625.8323 | -0.0022 | 7.6 |
| 5+ | 750.7999 | 750.7973 | -0.0026 | 56.6 |
| 4+ | 938.2481 | 938.2448 | -0.0033 | 100.0 |
| 3+ | 1250.6616 | 1250.6573 | -0.0043 | 53.7 |
| 2+ | 1875.4888 | 1875.4823 | -0.0065 | 8.6 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 6.99 |
| Counter-ion (TFA) | ion chromatography | 7.88 |
| Residual solvent + inorganic residue | estimated | 0.48 |
| Total peptide content | by difference | 84.65 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 98.30 | 98.55 | divergence +0.09 pp vs batch median |
| Total impurities (% area) | 1.70 | 1.45 | |
| Largest single impurity (% area) | not stated | 1.04 | |
| Water (%) | 6.3 | 6.99 | |
| Counter-ion (%) | 5.5 | 7.88 | |
| Peptide content (%w/w) | 87.6 | 84.65 | |
| Endotoxin (EU/mg) | 0.17 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Supplier-supplied
- Evidentiary weight
- Weaker evidence. Read with the caveat below.
- Chain of custody
- Supplier despatch → laboratory direct (courier, cold pack, 2 d) → assay. Submitter did not handle the vial.
- Assay date
- 09 Sep 2025
- Submitted to the index
- 13 Sep 2025
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot MKM-2508-P3929 n=10
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-020353 | MKM-2508-P3929 | VendorInvestigate | 2025-Q3 | 97.54 | 6.62 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2025-020354 | MKM-2508-P3929 | Janoshik | 2025-Q3 | 97.96 | 6.08 | 90.0 | Supplier-supplied | 0 | PASS |
| AX-2025-020355 | MKM-2508-P3929 | Medutest | 2025-Q3 | 98.85 | 6.89 | — | Supplier-supplied | 0 | PASS |
| AX-2025-020356 | MKM-2508-P3929 | PeptideMeter | 2025-Q3 | 98.08 | 6.66 | 103.5 | Supplier-supplied | 0 | PASS |
| AX-2025-020357 | MKM-2508-P3929 | Medutest | 2025-Q3 | 98.58 | 6.30 | — | Supplier-supplied | 0 | FAIL |
| AX-2025-020358 | MKM-2508-P3929 | Medutest | 2025-Q3 | 98.55 | 6.63 | — | Supplier-supplied | 1 | FAIL |
| AX-2025-020359 | MKM-2508-P3929 | Medutest | 2025-Q3 | 97.84 | 7.40 | — | Supplier-supplied | 1 | FAIL |
| AX-2025-020360 | MKM-2508-P3929 | Janoshik | 2025-Q3 | 98.25 | 7.39 | — | Supplier-supplied | 0 | PASS |
| AX-2025-020362 | MKM-2508-P3929 | Janoshik | 2025-Q3 | 98.16 | 7.03 | 101.8 | Supplier-supplied | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041275 | WWB | WWB-2607-X2189 | Nordanalyt | 2026-Q3 | 99.61 | 5.03 | 97.3 | Supplier-supplied | 0 | PASS |
| AX-2026-043335 | CPC | CPC-2602-G1978 | Janoshik | 2026-Q3 | 97.29 | 4.91 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-043332 | CPC | CPC-2602-G1978 | Janoshik | 2026-Q3 | 97.16 | 4.88 | 91.3 | Supplier-supplied | 1 | FAIL |
| AX-2026-041271 | WWB | WWB-2607-X2189 | Medutest | 2026-Q3 | 99.93 | 5.24 | 95.8 | Supplier-supplied | 0 | PASS |
| AX-2026-043336 | CPC | CPC-2602-G1978 | Janoshik | 2026-Q3 | 97.69 | 4.58 | 104.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041652 | QSC | QSC-2605-W8602 | Nordanalyt | 2026-Q3 | 99.33 | 6.55 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041273 | WWB | WWB-2607-X2189 | Janoshik | 2026-Q3 | 99.87 | 4.27 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041272 | WWB | WWB-2607-X2189 | Janoshik | 2026-Q3 | 99.15 | 4.12 | 97.2 | Supplier-supplied | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042943 | Adipotide | MKM-2606-K4013 | Janoshik | 2026-Q3 | 97.92 | 6.31 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042891 | CJC-1295 (no DAC) | MKM-2603-V2347 | Janoshik | 2026-Q3 | 99.28 | 3.63 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042942 | Adipotide | MKM-2606-K4013 | VendorInvestigate | 2026-Q3 | 97.04 | 5.56 | 94.6 | Buyer-sourced | 1 | FAIL |
| AX-2026-042914 | Gonadorelin | MKM-2604-A2596 | Janoshik | 2026-Q2 | 99.93 | 5.19 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042884 | BPC-157 | MKM-2605-X2575 | Nordanalyt | 2026-Q2 | 98.12 | 2.89 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-042946 | Tirzepatide | MKM-2601-L3752 | Medutest | 2026-Q2 | 97.71 | 8.10 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042911 | Gonadorelin | MKM-2604-A2596 | Medutest | 2026-Q2 | 99.08 | 5.55 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042932 | L-Glutathione (reduced) | MKM-2511-F2902 | Janoshik | 2026-Q2 | 98.57 | 8.41 | 92.9 | Supplier-supplied | 1 | MARGINAL |